Aldeyra Therapeutics Reports $33.8 Million Net Loss for 2025, Decreased R&D Expenses

Aldeyra Therapeutics, Inc. reported a net loss of approximately $33.8 million for the year ended December 31, 2025, a decrease from a net loss of $55.9 million in the previous year. The company's total stockholders' equity stood at $44.3 million as of the end of 2025. The reduction in losses was primarily attributed to a significant decrease in research and development expenses, which fell to $25.7 million from $48.2 million in 2024. This decline was driven by lower external clinical development costs, drug product manufacturing costs, and personnel expenses. General and administrative expenses also decreased by approximately $2.3 million, reflecting reduced personnel and legal expenditures.

Aldeyra's financial performance was influenced by its ongoing clinical trials and regulatory activities, particularly concerning its lead product candidate, reproxalap, which is being developed for dry eye disease and allergic conjunctivitis. The company entered into an exclusive option agreement with AbbVie Inc. on October 31, 2023, granting AbbVie the option to collaborate on the development and commercialization of reproxalap. AbbVie has made a non-refundable payment of $1.0 million and extended the option period with an additional $5.0 million payment. If the collaboration agreement is executed, AbbVie would pay a $100 million upfront cash payment, with potential milestone payments of up to $300 million.

The company has faced challenges in its regulatory submissions, receiving Complete Response Letters from the FDA regarding its New Drug Application (NDA) for reproxalap, indicating that additional studies may be required to demonstrate efficacy. Aldeyra plans to conduct further clinical trials to address the FDA's concerns and has initiated two chamber trials to assess ocular discomfort in dry eye patients. The company anticipates that its cash and cash equivalents, totaling $70 million as of December 31, 2025, will be sufficient to fund its projected operating expenses and debt obligations for at least the next twelve months.

Aldeyra's research and development strategy focuses on immune-mediated diseases, with additional product candidates in its pipeline, including ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa. The company has indicated that it may need to raise additional capital through equity or debt financing to support its ongoing development efforts and potential commercialization activities. The overall success of Aldeyra's product candidates remains contingent on obtaining regulatory approvals and achieving market acceptance, which are subject to various risks and uncertainties inherent in the biopharmaceutical industry.